Immunotherapy for cardiovascular disease
Abstract. The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver
Related Articles
Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardi
Abstract. After experiencing an acute coronary syndrome (ACS), patients are at a high risk of suffering from recurrent ischaemic cardiovascular events, esp
Management of cardiogenic shock: state-of-the-art
Intensive Care Medicine – The management of cardiogenic shock is an ongoing challenge. Despite all efforts and tremendous use of resources, mortality remains high. Whilst…
Platelets, Biomarkers of Coagulation and Fibrinolysis, and Early Coronary Stent Thrombosis
Background/Objectives: Acute stent thrombosis (ST) is a rare yet severe complication following percutaneous coronary intervention (PCI). Herein, we investigated the possible association between routinely available…
Association of ABO blood group with risk of coronary stent thrombosis
ABO blood group’s influence on cardiovascular risk, particularly in venous thromboembolism and coronary artery disease (CAD), is well-studied, with non-O blood groups associated with heightened…
Apixaban and Limiting Aspirin for Patients With Atrial Fibrillation, Percutaneous Coronary Intervention, and Multimorbidity:
AbstractBackgroundPatients with atrial fibrillation (AF) after an acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI) with multiple comorbidities are at increas…
Lipid-lowering therapy after acute coronary syndromes: a… : Coronary Artery Disease
ts between 2021–2022 and acquired data on LLT and lipid levels on admission and during 1-year posthospitalization. We compared plasma lipid changes and adherence to…
Management of cardiogenic shock: state-of-the-art
Intensive Care Medicine – The management of cardiogenic shock is an ongoing challenge. Despite all efforts and tremendous use of resources, mortality remains high. Whilst…
Management of cardiogenic shock: state-of-the-art
Intensive Care Medicine – The management of cardiogenic shock is an ongoing challenge. Despite all efforts and tremendous use of resources, mortality remains high. Whilst…
When cardiovascular medicines should be discontinued
Abstract. An integral component of the practice of medicine is focused on the initiation of medications, based on clinical practice guidelines and underlyi